Glepaglutide clinical trials
Also written ZP1848.
How each study uses glepaglutide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the glepaglutide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses glepaglutide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSRecruitingPhase 3Zealand PharmaNCT07197944Written as Glepaglutide
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension TrialCompletedPhase 3Zealand PharmaNCT04881825Written as Glepaglutide
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBSCompletedPhase 3Zealand PharmaNCT03905707Written as glepaglutide
- Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel SyndromeActive, not recruitingPhase 3Zealand PharmaNCT07228403Written as Glepaglutide 10 mg
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)CompletedPhase 3Zealand PharmaNCT03690206Written as glepaglutide
- The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel SyndromeCompletedPhase 3Zealand PharmaNCT04991311Written as Glepaglutide
- A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.CompletedPhase 1Zealand PharmaNCT04318743Written as Glepaglutide
- Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal FunctionCompletedPhase 1Zealand PharmaNCT04178447Written as Glepaglutide
- Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy SubjectsCompletedPhase 1Zealand PharmaNCT03279302Written as Glepaglutide
- A Phase 2 Trial Testing ZP1848 in Patients With SBSCompletedPhase 2Zealand PharmaNCT02690025Written as ZP1848
- Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending DoseCompletedPhase 1Zealand PharmaNCT00868660Written as ZP1848
Codes
What other systems call glepaglutide · ClinicalTrials.gg INT002118
- MeSH (NLM) C000731534glepaglutideOne source NLM
- UNII (FDA) 4M3C1913N6GLEPAGLUTIDEConfirmed FDA, NLM
- NCI Thesaurus C166765GlepaglutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731534 | glepaglutide | One source NLM |
| UNII (FDA) | 4M3C1913N6 | GLEPAGLUTIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C166765 | Glepaglutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.